Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Cohen on Eligibility for Ablation Therapy in Liver Cancer

September 19th 2019

Emil Israel Cohen, MD, an assistant professor at Medstar Georgetown University Hospital, discusses the criteria for ablation therapy in patients with liver cancer.

Dr. Richards on PARP Inhibition in Pancreatic Cancer

September 19th 2019

Donald A. Richards, MD, PhD, medical oncologist, Texas Oncology, discusses PARP inhibition in patients with pancreatic cancer.

Subset of BRAF non-V600-Mutant mCRC Is Potentially More Sensitive to Anti-EGFR Therapy

September 18th 2019

Patients with metastatic colorectal cancer who harbored BRAF non-V600, RAS-dependent mutations were more likely to respond to anti-EGFR therapy versus those with BRAF non-V600, RAS-independent mutations.

Dr. Manji on Treatment for NTRK Fusion+ CRC

September 18th 2019

Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.

ISGIO Presents 16th Annual Gastrointestinal Oncology Conference

September 17th 2019

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

Key Takeaway 8: MSI-High Status and HER2 Amplification

September 16th 2019

Key Takeaway 7: Role of Immunotherapy in MSI-High MCRC

September 16th 2019

Key Takeaway 6: I/O: Combination vs Monotherapy

September 16th 2019

Key Takeaway 5: Dosing of Multiple Kinase Inhibitors

September 16th 2019

Key Takeaway 4: Right-Sided Tumors: Anti-Angiogenic Treatment

September 16th 2019

Key Takeaway 3: Determining Tumor Mutational Status

September 16th 2019

Key Takeaway 2: Frontline Neoadjuvant Chemotherapy

September 16th 2019

Key Takeaway 1: Adjuvant Therapy Optimal Duration

September 16th 2019

Dr. Lieu Discusses the Focus of Future Research in mCRC

September 12th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses where future research should focus in metastatic colorectal cancer.

Gaining Ground in GI Cancers in Denver

September 11th 2019

We traveled to Denver, Colorado, for a State of the Science Summit™ on Gastrointestinal Cancers, which featured insights from University of Colorado and Rocky Mountain Cancer Centers faculty.

The Future of Personalized Therapy in Advanced HCC

September 10th 2019

Combinations May Be the Future in HCC

September 10th 2019

Optimal Management of Early-Stage HCC

September 10th 2019

Pancreatic NETs Subtypes Could Signal Risk of Recurrence

September 9th 2019

Two distinct subtypes of nonfunctional pancreatic neuroendocrine tumors could help prognosticate risk of recurrence following surgery.

Dr. Fakih on Future Directions in CRC

September 6th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses future directions in metastatic colorectal cancer (mCRC).